* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operati...
INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced t...
- Distinguished industry leaders with extensive track records in quality assurance and regulatory a...
* Recorded Q2'23 consolidated revenue of KRW 866.2 billion * Recorded Q2'23 consolidated operati...
INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contr...
- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest ...
* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operat...
* The company plans to begin construction in the first half of 2023 and commence operations in 20...
* Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit ofKRW 312.8 billion....
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * Th...
* Recorded consolidated revenue of KRW 873 billion in Q3'22 * Recorded consolidated operating pr...
* Receives accreditation for information security management system, information security in clou...
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Par...
* Two distinctive platforms will streamline the antibody development process. * With an advanced ...
* Rising from last year's ranking, the company's united effort and dedication to integrating sust...
* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO ...
* Released consolidated financial position of the company based on its full acquisition of Samsun...
* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans ...
* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its op...
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit o...